Clinical Research

Contact Info


The Mahkota Clinical Research Centre (CRC) was set up to conduct quality and ethical clinical trials in our efforts to play a role in the advancement of medical treatment. We have conducted various clinical trials of different disciplines including cancer, hypertension and diabetes.

Clinical Trials are conducted by doctors who are Good Clinical Practice (GCP) certified. Together with our team of pharmacists, laboratory scientists and nurses, patients are carefully traced throughout the trials conducted.

Good Clinical Practice is defined as

A standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate, and that the rights, integrity, and confidentiality of trial subjects are protected.



Clinical Research

Clinical Research Centre, Mahkota Medical Centre is pleased to announce active clinical trials on-going as below:

No. Protocol ID Study Title Investigator(s)
1. Samson-II A Randomized, Double-blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
Download to learn more
Dr Sanjeev Chandra Joshi / Dr Hayani Abd. Wahid

Should you require further information, kindly contact the respective Principal Investigators or Ms Loo Siew Mei at +606-285 2946 / loo.sm@mahkotamedical.com

Trials with patients still ongoing treatment but have stopped recruitment.

No. Protocol ID Study Title Investigator(s)
1. Z100-01 Randomized, Double-Blind, Placebo-Controlled Trial of Z-100 Plus Radiation Therapy in Patients With Local Advanced Cervical Cancer – A Phase III Trial Dr Sanjeev Chandra Joshi
2. ARISE A multi-center prospective non-interventional study investigating the clinical effectiveness of Ryzodeg® (Insulin Degludec/Insulin Aspart) in patients with type 2 diabetes mellitus in a real world setting Dr Lim Siang Chin / Dr Yew Shiong Shiong

Trials that have been completed and closed-out.

No. Protocol ID Study Title Investigator(s)
1. IHN01 Phase III double-blind, placebo-controlled study of post-operative adjuvant concurrent chemoradiotherapy (CTRT) with or without Nimotuzumab for Stage III/IV head and neck squamous cell cancer Dr Sanjeev Chandra Joshi
2. EXCELLENCE An Observational Study on Prevalent AntiHypertensive Prescription Practices in Private Hospitals in Malaysia Dr Ashok Philip / Dr Yew Shiong Shiong
3. GP13-301 A randomized, controlled, double-blind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs. MabThera® plus cyclophosphamide, vincristine, prednisone, followed by GP2013 or MabThera® maintenance therapy in patients with previously untreated, advanced stage follicular lymphoma Dr Kok Keng Weng
4. BV-NSCLC-002 A Phase III, open-label, multicentre, randomised trial to establish safety and efficacy of an EGF cancer vaccine in inoperable, late stage (IIIb/IV) biomarker positive Non Small Cell Lung Carcinoma (NSCLC) patients eligible to receive standard treatment and supportive care Dr Sanjeev Chandra Joshi
5. B7391003 A Phase 3 Randomized, Double-Blind Study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Pacitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer Dr Sanjeev Chandra Joshi
6. IMCL CP12-0919 A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH) Dr Jayendran Dharmaratnam
7. LA-EP06-302 Pivotal study in breast cancer patients investigating efficacy and safety of LA-EP2006 and Neulasta® Dr Jayendran Dharmaratnam

Contact Info

Telephone: +606-285 2946
Email: loo.sm@mahkotamedical.com

Operating Hours:

8am – 5pm  (Monday – Friday)